Isbn: 9783031386220 - pancreatic cancer: current therapeutics and future directions (15 resultados)

ISBN
Refinar con la Búsqueda avanzada

Filtrar la búsqueda

  • Libros (15)

a

Intervalo de precios personalizado (EUR)

a

  • Idioma: Inglés

    Editorial: Springer, 2023

    3031386221 / 9783031386220

    • Tapa dura

    Librería: Open Books, Chicago, IL, Estados Unidos de AmericaOpen Books

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 111,13

    Envío por EUR 3,48 
    Se envía dentro de Estados Unidos de America

    Cantidad disponible: 2 disponibles

    hardcover. Condición: New. Open Books is a nonprofit social venture that provides literacy experiences for thousands of readers each year through inspiring programs and creative capitalization of books.

  • Idioma: Inglés

    Editorial: Springer, 2023

    3031386221 / 9783031386220

    • Tapa dura

    Librería: Brook Bookstore On Demand, Napoli, NA, ItaliaBrook Bookstore On Demand

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 110,26

    Envío por EUR 6,80 
    Se envía de Italia a Estados Unidos de America

    Cantidad disponible: 10 disponibles

    Condición: new.

  • Idioma: Inglés

    Editorial: Springer International Publishing AG, Cham, 2023

    3031386221 / 9783031386220

    • Tapa dura

    Librería: Grand Eagle Retail, Bensenville, IL, Estados Unidos de AmericaGrand Eagle Retail

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 124,83

     Gastos de envío gratis 
    Se envía dentro de Estados Unidos de America

    Cantidad disponible: 1 disponibles

    Hardcover. Condición: new. Hardcover. Pancreatic cancer is a challenging and complex disease characterized by a dense fibrotic stroma and an immunosuppressive tumor microenvironment. Until recently, there were no predictive biomarkers to personalize selection of targeted or biologic therapies as a part of standard of care treatment. Moreover, the regulatory immune population of cells creates a cold, non-immunogenic tumor that is resistant to immunotherapies including checkpoint inhibitors. However, in the last few years, there has been substantial progress in our understanding of the role mutations in the pathogenesis of disease leading to increased adoption of germline and next generation sequencing to identify mutations and fusions to optimize selection of therapies and select patients for clinical trials of targeted agents.This book provides a comprehensive, global overview on therapy for pancreatic cancer, exploring approved therapies and focusing on the Next in drug development including molecularly targeted therapy and efforts at Drugging the Undruggable: the KRAS mutation. It also addresses efforts at targeting the inhospitable stroma to improve drug delivery to the tumor cells, incorporating ct DNA (liquid biopsies) in the care of patients and recent advances in immunotherapy. Pancreatic Cancer: Current Therapeutics and Future Directions will illuminate these challenges, review existing therapeutics, and highlight current and future efforts to improve outcomes in this devastating disease. Useful to physicians, fellows, medical students, residents, physician assistants, nurse practitioners, pharmaceutical companies and researchers interested in pancreatic cancer, it will first explain management of localized disease including resectability and adjuvant and neoadjuvant therapies. Targeted therapies including molecular, immunotherapy, stroma and role of ctDNA or liquidbiopsies will be addressed. Finally, the book will explore the important role of pain management, diet and exercise in improving outcomes in pancreatic cancer. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.

  • Idioma: Inglés

    Editorial: Springer, 2023

    3031386221 / 9783031386220

    • Tapa dura

    Librería: Brook Bookstore, Milano, MI, ItaliaBrook Bookstore

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 105,52

    Envío por EUR 27,99 
    Se envía de Italia a Estados Unidos de America

    Cantidad disponible: 10 disponibles

    Condición: new.

  • Idioma: Inglés

    Editorial: Springer Nature, 2023

    3031386221 / 9783031386220

    • Tapa dura

    Librería: Revaluation Books, Exeter, Reino UnidoRevaluation Books

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 132,15

    Envío por EUR 11,66 
    Se envía de Reino Unido a Estados Unidos de America

    Cantidad disponible: 2 disponibles

    Hardcover. Condición: Brand New. 203 pages. 9.25x6.10x0.75 inches. In Stock.

  • Idioma: Inglés

    Editorial: Springer International Publishing AG, Cham, 2023

    3031386221 / 9783031386220

    • Tapa dura

    Librería: AussieBookSeller, Truganina, VIC, AustraliaAussieBookSeller

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 136,50

    Envío por EUR 32,23 
    Se envía de Australia a Estados Unidos de America

    Cantidad disponible: 1 disponibles

    Hardcover. Condición: new. Hardcover. Pancreatic cancer is a challenging and complex disease characterized by a dense fibrotic stroma and an immunosuppressive tumor microenvironment. Until recently, there were no predictive biomarkers to personalize selection of targeted or biologic therapies as a part of standard of care treatment. Moreover, the regulatory immune population of cells creates a cold, non-immunogenic tumor that is resistant to immunotherapies including checkpoint inhibitors. However, in the last few years, there has been substantial progress in our understanding of the role mutations in the pathogenesis of disease leading to increased adoption of germline and next generation sequencing to identify mutations and fusions to optimize selection of therapies and select patients for clinical trials of targeted agents.This book provides a comprehensive, global overview on therapy for pancreatic cancer, exploring approved therapies and focusing on the Next in drug development including molecularly targeted therapy and efforts at Drugging the Undruggable: the KRAS mutation. It also addresses efforts at targeting the inhospitable stroma to improve drug delivery to the tumor cells, incorporating ct DNA (liquid biopsies) in the care of patients and recent advances in immunotherapy. Pancreatic Cancer: Current Therapeutics and Future Directions will illuminate these challenges, review existing therapeutics, and highlight current and future efforts to improve outcomes in this devastating disease. Useful to physicians, fellows, medical students, residents, physician assistants, nurse practitioners, pharmaceutical companies and researchers interested in pancreatic cancer, it will first explain management of localized disease including resectability and adjuvant and neoadjuvant therapies. Targeted therapies including molecular, immunotherapy, stroma and role of ctDNA or liquidbiopsies will be addressed. Finally, the book will explore the important role of pain management, diet and exercise in improving outcomes in pancreatic cancer. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability.

  • Idioma: Inglés

    Editorial: Springer, Berlin|Springer International Publishing|Springer, 2023

    3031386221 / 9783031386220

    • Tapa dura

    Librería: moluna, Greven, Alemaniamoluna

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 115,65

    Envío por EUR 48,99 
    Se envía de Alemania a Estados Unidos de America

    Cantidad disponible: Más de 20 disponibles

    Condición: New.

  • Idioma: Inglés

    Editorial: Springer, 2023

    3031386221 / 9783031386220

    • Tapa dura

    Librería: Books Puddle, Woodside, NY, Estados Unidos de AmericaBooks Puddle

    Vendedor de 4 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 179,53

    Envío por EUR 3,48 
    Se envía dentro de Estados Unidos de America

    Cantidad disponible: 4 disponibles

    Condición: New.

  • Idioma: Inglés

    Editorial: Springer, 2023

    3031386221 / 9783031386220

    • Tapa dura

    Librería: Buchpark, Trebbin, AlemaniaBuchpark

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Usado

    EUR 101,63

    Envío por EUR 105,00 
    Se envía de Alemania a Estados Unidos de America

    Cantidad disponible: 1 disponibles

    Condición: Hervorragend. Zustand: Hervorragend | Sprache: Englisch | Produktart: Bücher | Pancreatic cancer is a challenging and complex disease characterized by a dense fibrotic stroma and an immunosuppressive tumor microenvironment. Until recently, there were no predictive biomarkers to personalize selection of targeted or biologic therapies as a part of standard of care treatment. Moreover, the regulatory immune population of cells creates a ¿cold¿, non-immunogenic tumor that is resistant to immunotherapies including checkpoint inhibitors. However, in the last few years, there has been substantial progress in our understanding of the role mutations in the pathogenesis of disease leading to increased adoption of germline and next generation sequencing to identify mutations and fusions to optimize selection of therapies and select patients for clinical trials of targeted agents.This book provides a comprehensive, global overview on therapy for pancreatic cancer, exploring approved therapies and focusing on the ¿Next¿ in drug development including molecularly targeted therapy and efforts at ¿Drugging the Undruggable¿: the KRAS mutation. It also addresses efforts at targeting the inhospitable stroma to improve drug delivery to the tumor cells, incorporating ct DNA (liquid biopsies) in the care of patients and recent advances in immunotherapy. Pancreatic Cancer: Current Therapeutics and Future Directions will illuminate these challenges, review existing therapeutics, and highlight current and future efforts to improve outcomes in this devastating disease. Useful to physicians, fellows, medical students, residents, physician assistants, nurse practitioners, pharmaceutical companies and researchers interested in pancreatic cancer, it will first explain management of localized disease including resectability and adjuvant and neoadjuvant therapies. Targeted therapies including molecular, immunotherapy, stroma and role of ctDNA or ¿liquidbiopsies¿ will be addressed. Finally, the book will explore the important role of pain management, diet and exercise in improving outcomes in pancreatic cancer.

  • Idioma: Inglés

    Editorial: Springer, 2023

    3031386221 / 9783031386220

    • Tapa dura

    Librería: AHA-BUCH GmbH, Einbeck, AlemaniaAHA-BUCH GmbH

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 195,51

    Envío por EUR 30,50 
    Se envía de Alemania a Estados Unidos de America

    Cantidad disponible: 1 disponibles

    Buch. Condición: Neu. Druck auf Anfrage Neuware - Printed after ordering - Pancreatic cancer isachallengingandcomplex diseasecharacterized by a dense fibrotic stroma and an immunosuppressive tumor microenvironment.Until recently, there were no predictive biomarkers to personalize selection of targeted or biologic therapies as a part of standard of care treatment. Moreover,theregulatory immune population of cells creates a 'cold', non-immunogenic tumor that is resistanttoimmunotherapies including checkpoint inhibitors. However, in the last few years, there has been substantial progress in our understanding of the role mutations in the pathogenesis of disease leading to increased adoption of germline and next generation sequencing to identify mutations and fusions to optimize selection of therapies and select patients for clinical trials of targeted agents.This book provides a comprehensive, global overview ontherapy forpancreatic cancer, exploringapproved therapiesand focusingon the 'Next' in drug development including molecularly targeted therapy and efforts at 'Drugging the Undruggable': the KRAS mutation. It also addresses efforts at targeting the inhospitable stroma to improve drug delivery to the tumor cells, incorporating ct DNA (liquid biopsies) in the care of patients and recent advances in immunotherapy. Pancreatic Cancer: Current Therapeutics and Future Directionswill illuminate these challenges, review existing therapeutics, and highlight current and future efforts to improve outcomes in this devastating disease. Useful to physicians, fellows, medical students, residents, physician assistants, nurse practitioners, pharmaceutical companies and researchers interested in pancreatic cancer, it will firstexplain management of localized disease includingresectability and adjuvant and neoadjuvant therapies. Targeted therapies including molecular, immunotherapy, stromaand role of ctDNA or 'liquidbiopsies'will be addressed. Finally, the book will explore the important role of pain management,diet andexercisein improving outcomes in pancreatic cancer.

  • Idioma: Inglés

    Editorial: Springer, 2023

    3031386221 / 9783031386220

    • Tapa dura

    Librería: BUCHSERVICE / ANTIQUARIAT Lars Lutzer, Wahlstedt, AlemaniaBUCHSERVICE / ANTIQUARIAT Lars Lutzer

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Usado - Bueno

    EUR 299,90

    Envío por EUR 39,95 
    Se envía de Alemania a Estados Unidos de America

    Cantidad disponible: 1 disponibles

    Hardcover. Condición: gut. 2023. Pancreatic Cancer In deutscher Sprache. pages.

  • Idioma: Inglés

    Editorial: Springer International Publishing Okt 2023, 2023

    3031386221 / 9783031386220

    • Tapa dura
    • Impresión bajo demanda

    Librería: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, AlemaniaBuchWeltWeit Ludwig Meier e.K.

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 139,09

    Envío por EUR 23,00 
    Se envía de Alemania a Estados Unidos de America

    Cantidad disponible: 2 disponibles

    Buch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Pancreatic cancer isachallengingandcomplex diseasecharacterized by a dense fibrotic stroma and an immunosuppressive tumor microenvironment.Until recently, there were no predictive biomarkers to personalize selection of targeted or biologic therapies as a part of standard of care treatment. Moreover,theregulatory immune population of cells creates a 'cold', non-immunogenic tumor that is resistanttoimmunotherapies including checkpoint inhibitors. However, in the last few years, there has been substantial progress in our understanding of the role mutations in the pathogenesis of disease leading to increased adoption of germline and next generation sequencing to identify mutations and fusions to optimize selection of therapies and select patients for clinical trials of targeted agents.This book provides a comprehensive, global overview ontherapy forpancreatic cancer, exploringapproved therapiesand focusingon the 'Next' in drug development including molecularly targeted therapy and efforts at 'Drugging the Undruggable': the KRAS mutation. It also addresses efforts at targeting the inhospitable stroma to improve drug delivery to the tumor cells, incorporating ct DNA (liquid biopsies) in the care of patients and recent advances in immunotherapy. Pancreatic Cancer: Current Therapeutics and Future Directionswill illuminate these challenges, review existing therapeutics, and highlight current and future efforts to improve outcomes in this devastating disease. Useful to physicians, fellows, medical students, residents, physician assistants, nurse practitioners, pharmaceutical companies and researchers interested in pancreatic cancer, it will firstexplain management of localized disease includingresectability and adjuvant and neoadjuvant therapies. Targeted therapies including molecular, immunotherapy, stromaand role of ctDNA or 'liquid biopsies'will be addressed. Finally, the book will explore the important role of pain management,diet andexercisein improving outcomes in pancreatic cancer. 204 pp. Englisch.

  • Idioma: Inglés

    Editorial: Springer, 2023

    3031386221 / 9783031386220

    • Tapa dura
    • Impresión bajo demanda

    Librería: Majestic Books, Hounslow, Reino UnidoMajestic Books

    Vendedor de 4 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 186,08

    Envío por EUR 7,58 
    Se envía de Reino Unido a Estados Unidos de America

    Cantidad disponible: 4 disponibles

    Condición: New. Print on Demand.

  • Idioma: Inglés

    Editorial: Springer, 2023

    3031386221 / 9783031386220

    • Tapa dura
    • Impresión bajo demanda

    Librería: Biblios, frankfurt am main, HESSE, AlemaniaBiblios

    Vendedor de 4 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 188,77

    Envío por EUR 9,95 
    Se envía de Alemania a Estados Unidos de America

    Cantidad disponible: 4 disponibles

    Condición: New. PRINT ON DEMAND.

  • Idioma: Inglés

    Editorial: Springer, Palgrave Macmillan Nov 2023, 2023

    3031386221 / 9783031386220

    • Tapa dura
    • Impresión bajo demanda

    Librería: buchversandmimpf2000, Emtmannsberg, BAYE, Alemaniabuchversandmimpf2000

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 139,09

    Envío por EUR 60,00 
    Se envía de Alemania a Estados Unidos de America

    Cantidad disponible: 1 disponibles

    Buch. Condición: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Pancreatic cancer is a challenging and complex disease characterized by a dense fibrotic stroma and an immunosuppressive tumor microenvironment. Until recently, there were no predictive biomarkers to personalize selection of targeted or biologic therapies as a part of standard of care treatment. Moreover, the regulatory immune population of cells creates a 'cold', non-immunogenic tumor that is resistant to immunotherapies including checkpoint inhibitors. However, in the last few years, there has been substantial progress in our understanding of the role mutations in the pathogenesis of disease leading to increased adoption of germline and next generation sequencing to identify mutations and fusions to optimize selection of therapies and select patients for clinical trials of targeted agents.This book provides a comprehensive, global overview on therapy for pancreatic cancer, exploring approved therapies and focusing on the 'Next' in drug development including molecularly targeted therapy and efforts at 'Drugging the Undruggable': the KRAS mutation. It also addresses efforts at targeting the inhospitable stroma to improve drug delivery to the tumor cells, incorporating ct DNA (liquid biopsies) in the care of patients and recent advances in immunotherapy.Pancreatic Cancer: Current Therapeutics and Future Directions will illuminate these challenges, review existing therapeutics, and highlight current and future efforts to improve outcomes in this devastating disease. Useful to physicians, fellows, medical students, residents, physician assistants, nurse practitioners, pharmaceutical companies and researchers interested in pancreatic cancer, it will first explain management of localized disease including resectability and adjuvant and neoadjuvant therapies. Targeted therapies including molecular, immunotherapy, stroma and role of ctDNA or 'liquidbiopsies' will be addressed. Finally, the book will explore the important role of pain management, diet and exercise in improving outcomes in pancreatic cancer.Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 204 pp. Englisch.